Journal of Diabetes Research / 2018 / Article / Tab 2

Research Article

Insulin Secretion and Risk for Future Diabetes in Subjects with a Nonpositive Insulinogenic Index

Table 2

Baseline characteristics by level of the insulinogenic index.

Positive insulinogenic indexNonpositive insulinogenic index
Insulinogenic index ≥ 0.4
()
Insulinogenic index < 0.4
()
ΔGlu0–30 ≤ 0
()
ΔIns0–30 ≤ 0
()

Age (years)51.6 ± 7.052.9 ± 6.750.6 ± 7.150.2 ± 8.5
Male gender (%)65.379.542.963.3
Body mass index (kg/m2)24.3 ± 3.323.6 ± 2.922.4 ± 2.724.8 ± 4.3‡
Fasting plasma glucose (mg/dL)92/96/10194/99/10688/91/9592/98/108‡
30 min plasma glucose (mg/dL)126/143/162150/168/18676/81/88132/163/182‡
1-hour plasma glucose (mg/dL)106/131/159146/178/20572/92/101112/151/192
2-hour plasma glucose (mg/dL)96/109/126105/123/14681/92/11190/120/142‡
Fasting insulin (μIU/mL)3.1/4.3/6.22.6/3.3/4.32.8/4.2/4.72.4/3.3/6.2
30 min insulin (μIU/mL)29.2/40.2/58.313.7/19.1/24.113.7/20.1/32.90.8/1.4/2.1†‡
120 min insulin (μIU/mL)16.3/24.6/39.714.5/21.5/34.99.1/15.3/21.910.6/23.0/39.1
HbA1c (%)5.2 ± 0.35.3 ± 0.45.1 ± 0.3†5.3 ± 0.4
Glucose tolerance
 Normal glucose tolerance (%)62.239.492.946.7‡
 Impaired fasting glucose (%)32.149.87.243.3
 Impaired glucose tolerance (%)13.230.92.430.0
Current smokers (%)17.525.019.020.0
Drinkers (%)59.971.342.9†63.3
Antihypertensive medications (%)13.614.67.110.0
Lipid-lowering medications (%)6.97.32.46.7

Data are expressed as mean ± standard deviation, 25/50/75th percentile values, or %. Characteristics among groups were compared using one-way ANOVA for continuous variables and chi-square tests for categorical variables with Bonferroni correction for multiple comparisons. compared to insulinogenic index ≥ 0.4, compared to insulinogenic index < 0.4, compared to ΔGlu0–30 ≤ 0. ΔGlu0–30 and ΔIns0–30, change in glucose and in insulin, respectively, over the first 30 min on the oral glucose tolerance test.